JAMA Cardiology

JAMA Cardiology(英文缩写 JAMA CARDIOL),ISSN 2380-6583,eISSN 2380-6591 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。

2026 年数据 · 影响因子
15.200
JCR 分区
Q1
CAS 分区
B1
近一年发文量
306
本站 PubMed 收录统计

发文量统计区间:2025-09-27 至 2026-09-27,按本站收录文献的发表日期统计。

ISSN: 2380-6583 · eISSN: 2380-6591 · 缩写: JAMA CARDIOL

期刊介绍

选择期刊介绍栏目

期刊简介

JAMA Cardiology 是美国医学会旗下心血管领域的顶级同行评议期刊,聚焦临床心脏病学的原创研究、权威综述与观点评论。内容覆盖冠心病、心力衰竭、心律失常、影像与预防等方向,强调证据质量与临床转化。读者群主要为心血管专科医师、内科医生、研究人员及公共卫生决策者,适合关注高水平临床证据与学科进展的专业人士。

研究方向

主要发表心血管疾病的临床研究、随机试验、队列与注册研究、系统综述及荟萃分析,也刊载指南解读、方法学讨论和临床挑战类文章。主题涵盖缺血性心脏病、心衰、电生理、结构性心脏病、预防与流行病学、影像与生物标志物等,兼顾诊疗策略与卫生政策。

期刊特色

研究取向以患者结局和临床实践为导向,重视方法严谨、样本代表性及结果可推广性。论文通常要求明确临床意义、规范统计分析和充分利益冲突披露。适合具备扎实研究设计能力、希望在高影响力平台发布心血管临床证据的团队,也适合读者跟踪学科前沿。

投稿难度

投稿难度较高,对创新性、样本量、统计严谨性和临床影响力均有严格要求。建议在投稿前完善研究设计、预设分析方案并规范报告,突出与既有证据的差异和实际应用价值。若被拒,可依据审稿意见补充分析或转投同领域专科期刊,不宜仅凭分区判断录用可能性。

历年影响因子趋势

JCR 数据年份影响因子JCR 分区
202130.157Q1
202224.000Q1
202314.800Q1
202414.100Q1
202515.200Q1

JAMA Cardiology 最新收录文献

  1. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    1. Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure: The FINEARTS-HF Randomized Clinical Trial.

    作者:
    John W Ostrominski, Finnian R Mc Causland, Brian L Claggett, Akshay S Desai, Pardeep S Jhund, Alasdair Henderson, Carolyn S P Lam, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, Meike Brinker, Patrick Schloemer, Katja Rohwedder, John J V McMurray, Scott D Solomon, Muthiah Vaduganathan
    日期:
    2026-09-23

    该文献暂无摘要。

  2. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    2. Interpreting 7-Year Valve Durability in PARTNER 3-Reply.

    作者:
    Philippe Pibarot, Julien Ternacle, Rebecca Hahn
    日期:
    2026-09-23

    该文献暂无摘要。

  3. JCR分区: Q1 CAS分区: B1 影响因子: 15.2
  4. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    4. Multidimensional Aging Trajectories Preceding Cardiovascular Events.

    作者:
    Aung Zaw Zaw Phyo, Zimu Wu, Andrew M Tonkin, Swarna Vishwanath, Sara E Espinoza, Rory Wolfe, Suzanne G Orchard, Robyn L Woods, David Gonzalez-Chica, Nigel Stocks, Joanne Ryan
    日期:
    2026-09-23

    Whether declines in functional aging markers precede cardiovascular (CVD) events is unclear. To determine 14-year trajectories of frailty, intrinsic capacity (IC), and physical health-related quality of life (HRQOL) preceding CVD events in later life and to compare these with matched CVD-free controls. This was a case-control study nested within the Aspirin in Reducing Events in the Elderly (ASPREE) cohort. Participants were aged 70 years and older (≥65 years for US racial and ethnic minoritized groups) with no prior CVD event, dementia, or significant physical disability and were recruited in Australia and the US between March 2010 and December 2014. Four controls were matched to each CVD case by age (±1 year), sex, and education. Participants were followed up prospectively until December 2024. Data were analyzed between January and May 2026. The 64-item Frailty Index (FI), Fried phenotype frailty, IC (comprising cognitive, locomotor, vitality, and psychological domains), and 12-item short form physical HRQOL were assessed annually. CVD events were adjudicated by expert clinical panels. Linear mixed-effects models were used to compare the trajectories between cases and controls. This study included 12 015 participants (2403 cases and 9612 controls) with a mean (SD) age of 76.4 (4.7) years; 6190 were male (52%). Compared with matched controls, individuals who went on to experience a CVD event had consistently worse profiles up to a decade beforehand, including higher frailty, lower IC, and poorer physical HRQOL. These differences widened markedly in the 5 years preceding the event. Cases showed faster deterioration over time, with greater increases in frailty (FI, β = 0.78; 95% CI, 0.66-0.91; Fried, β = 0.05; 95% CI, 0.03-0.07), and steeper declines in IC (β = -0.34; 95% CI, -0.44 to -0.24) and physical HRQOL (β = -0.55; 95% CI, -0.70 to -0.40). Patterns were broadly similar across components of the CVD composite, with the exception that divergence occurred earlier for heart failure and fatal coronary heart disease (≥10 years before the event) than for myocardial infarction or stroke. Results of this nested case-control study show that declines in functional aging markers were prominent before clinically apparent CVD, suggesting that they may represent the culmination of progressive multisystem aging and indicating a prolonged window of opportunity for closer clinical evaluation and early intervention.

  5. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    5. Interpreting 7-Year Valve Durability in PARTNER 3.

    作者:
    Mateo Marin-Cuartas, Samuel Heuts, Michael A Borger
    日期:
    2026-09-23

    该文献暂无摘要。

  6. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    6. Lipoprotein(a) and Incident Venous Thromboembolism.

    作者:
    Luke A Dreher, Hussein Abdul Nabi, Mahmoud Abdelnabi, Ramzi Ibrahim, Hunter VanDolah, Juan M Farina, David Simper, Steven J Lester, Said Alsidawi, Fadi E Shamoun, Chadi Ayoub, Reza Arsanjani
    日期:
    2026-09-23

    该文献暂无摘要。

  7. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    7. Coronary Computed Tomography Angiography and Plaque Analysis for Screening.

    作者:
    Alexander R Zheutlin, Jared A Spitz, John T Wilkins
    日期:
    2026-09-16

    该文献暂无摘要。

  8. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    8. An Axillary Mass in Pulmonary Embolism.

    作者:
    Wentao Yang, Chen Zhang, Yong Wang
    日期:
    2026-09-16

    该文献暂无摘要。

  9. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    9. The Future of Genetic Therapy for Inherited Cardiomyopathy.

    作者:
    Rosemary B Kirk, Alexander J Sparrow, Hugh Watkins
    日期:
    2026-09-16

    该文献暂无摘要。

  10. JCR分区: Q1 CAS分区: B1 影响因子: 15.2

    10. Pooled Prasugrel Doses in a P2Y12 Network Meta-Analysis.

    作者:
    Koichiro Yuji, Wakako Yuji
    日期:
    2026-09-16

    该文献暂无摘要。

在 JAMA Cardiology 中搜索更多文献

支持中英文检索 · 智能翻译 · 影响因子 · PDF 下载 · AI 文献阅读

指标接近的期刊